Fierce Biotech

Subscribe to Fierce Biotech feed
Updated: 5 hours 43 min ago

Illumina CEO says U.S. lags behind on catching COVID-19 mutations: CNBC

Fri, 01/22/2021 - 08:09
Illumina CEO says U.S. lags behind on catching COVID-19 mutations: CNBC chale Fri, 01/22/2021 - 11:09

Beyond COVID-19, where will biopharma focus in 2021?

Fri, 01/22/2021 - 07:48
Beyond COVID-19, where will biopharma focus in 2021? aalidrus Fri, 01/22/2021 - 10:48

FDA clears J&J's robotic surgery system for total knee replacements

Fri, 01/22/2021 - 07:12
FDA clears J&J's robotic surgery system for total knee replacements chale Fri, 01/22/2021 - 10:12

Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

Fri, 01/22/2021 - 05:36
Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post fkansteiner Fri, 01/22/2021 - 08:36

GlaxoSmithKline's R&D failures rack up, notching an Immutep-partnered trial cull

Fri, 01/22/2021 - 05:31
GlaxoSmithKline's R&D failures rack up, notching an Immutep-partnered trial cull badams Fri, 01/22/2021 - 08:31

Pfizer's R&D president Dolsten: Not taking government cash made us more nimble for COVID-19 vaccine

Fri, 01/22/2021 - 05:10
Pfizer's R&D president Dolsten: Not taking government cash made us more nimble for COVID-19 vaccine badams Fri, 01/22/2021 - 08:10

Incyte lands priority review for PD-1 inhibitor in anal cancer

Fri, 01/22/2021 - 04:45
Incyte lands priority review for PD-1 inhibitor in anal cancer ntaylor Fri, 01/22/2021 - 07:45

Tracking cancer metastasis with CRISPR opens new areas for drug development

Fri, 01/22/2021 - 04:32
Tracking cancer metastasis with CRISPR opens new areas for drug development aliu Fri, 01/22/2021 - 07:32

BIO lays off staff to adapt to another year of virtual events

Fri, 01/22/2021 - 02:52
BIO lays off staff to adapt to another year of virtual events ntaylor Fri, 01/22/2021 - 05:52

CDC study says Abbott's rapid COVID-19 antigen test may miss two-thirds of asymptomatic cases

Thu, 01/21/2021 - 12:16
CDC study says Abbott's rapid COVID-19 antigen test may miss two-thirds of asymptomatic cases chale Thu, 01/21/2021 - 15:16

Boston Scientific buys wearable heart monitor maker Preventice for $1.2B, as in-hospital sales take hit from pandemic

Thu, 01/21/2021 - 07:57
Boston Scientific buys wearable heart monitor maker Preventice for $1.2B, as in-hospital sales take hit from pandemic chale Thu, 01/21/2021 - 10:57

Another GSK vaccine exec jumps ship for biotech CEO role

Thu, 01/21/2021 - 06:57
Another GSK vaccine exec jumps ship for biotech CEO role aalidrus Thu, 01/21/2021 - 09:57

Plexium bumps up series A by $35M as it battles rivals in the new protein-degradation space

Thu, 01/21/2021 - 05:32
Plexium bumps up series A by $35M as it battles rivals in the new protein-degradation space badams Thu, 01/21/2021 - 08:32

Rallybio hires Tuch from BMO to lead corporate development

Thu, 01/21/2021 - 05:25
Rallybio hires Tuch from BMO to lead corporate development ntaylor Thu, 01/21/2021 - 08:25

Servier, MiNA ally to upregulate neurological disorder proteins using small activating RNAs

Thu, 01/21/2021 - 04:51
Servier, MiNA ally to upregulate neurological disorder proteins using small activating RNAs ntaylor Thu, 01/21/2021 - 07:51

Veru touts novel breast cancer treatment strategy as drug nears phase 3

Thu, 01/21/2021 - 04:46
Veru touts novel breast cancer treatment strategy as drug nears phase 3 aliu Thu, 01/21/2021 - 07:46

After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO

Thu, 01/21/2021 - 01:31
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO badams Thu, 01/21/2021 - 04:31

Haemonetics to buy bloodstopper medtech Cardiva Medical in $510M deal

Wed, 01/20/2021 - 07:59
Haemonetics to buy bloodstopper medtech Cardiva Medical in $510M deal chale Wed, 01/20/2021 - 10:59

In vitro test maker Ortho Clinical Diagnostics files $1.5B Nasdaq IPO

Wed, 01/20/2021 - 07:17
In vitro test maker Ortho Clinical Diagnostics files $1.5B Nasdaq IPO chale Wed, 01/20/2021 - 10:17

Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma

Wed, 01/20/2021 - 06:32
Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma arlene.weintraub Wed, 01/20/2021 - 09:32